Literature DB >> 33773277

Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology.

Anne Zaremba1, Georg Lodde2, Rajmohan Murali3, Manuel Philip2, Ioana Cosgarea4, Philipp Jansen2, Eleftheria Chorti2, Christian Rose5, Bernhard Hemmerlein6, Johanna Matull2, Carl M Thielmann2, Julia Kretz2, Inga Möller2, Antje Sucker2, Annette Paschen2, Elisabeth Livingstone2, Lisa Zimmer2, Susanne Horn7, Dirk Schadendorf2, Eva Hadaschik2, Klaus Griewank8.   

Abstract

Accurate classification of melanocytic proliferations has important implications for prognostic prediction, treatment and follow-up. Although most melanocytic proliferations can be accurately classified using clinical and pathological criteria, classification (specifically distinction between nevus and melanoma) can be challenging in a subset of cases, including those with spitzoid morphology. Genetic studies have shown that mutation profiles differ between primary melanoma subtypes and Spitz nevi. These differences may aid in distinguishing benign from malignant in some melanocytic tumours. Here, we present a selection of melanocytic proliferations with equivocal histopathological criteria, wherein genetic analysis was requested to help guide classification. In two of four cases, the genetic results offered valuable insights, allowing a definitive diagnosis, indicating the diagnostic value of mutation profiling in a real-world routine clinical setting. Although histopathological assessment remains decisive in melanocytic proliferation classification, we recommend including genetic profiling in cases of borderline or atypical lesion to support accurate classification.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atypical spitzoid lesion; Borderline tumour; Malignant melanoma; Mutation profiling; Spitz nevus; Spitzoid melanoma

Mesh:

Substances:

Year:  2021        PMID: 33773277      PMCID: PMC8087654          DOI: 10.1016/j.ejca.2021.02.025

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  27 in total

1.  SF3B1 and BAP1 mutations in blue nevus-like melanoma.

Authors:  Klaus G Griewank; Hansgeorg Müller; Louise A Jackett; Michael Emberger; Inga Möller; Johannes Ap van de Nes; Lisa Zimmer; Elisabeth Livingstone; Thomas Wiesner; Simone L Scholz; Ioana Cosgarea; Antje Sucker; Tobias Schimming; Uwe Hillen; Bastian Schilling; Annette Paschen; Henning Reis; Thomas Mentzel; Heinz Kutzner; Arno Rütten; Rajmohan Murali; Richard A Scolyer; Dirk Schadendorf
Journal:  Mod Pathol       Date:  2017-04-14       Impact factor: 7.842

2.  A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.

Authors:  Thomas Wiesner; Rajmohan Murali; Isabella Fried; Lorenzo Cerroni; Klaus Busam; Heinz Kutzner; Boris C Bastian
Journal:  Am J Surg Pathol       Date:  2012-06       Impact factor: 6.394

3.  Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.

Authors:  Marcory C R F van Dijk; Monique R Bernsen; Dirk J Ruiter
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

4.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

5.  The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment.

Authors:  Raymond L Barnhill
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

Review 6.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

7.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

8.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi.

Authors:  Iwei Yeh; Ursula E Lang; Emeline Durieux; Meng Kian Tee; Aparna Jorapur; A Hunter Shain; Veronique Haddad; Daniel Pissaloux; Xu Chen; Lorenzo Cerroni; Robert L Judson; Philip E LeBoit; Timothy H McCalmont; Boris C Bastian; Arnaud de la Fouchardière
Journal:  Nat Commun       Date:  2017-09-21       Impact factor: 14.919

View more
  1 in total

1.  Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.

Authors:  Anne Zaremba; Philipp Jansen; Rajmohan Murali; Anand Mayakonda; Anna Riedel; Manuel Philip; Christian Rose; Jörg Schaller; Hansgeorg Müller; Heinz Kutzner; Inga Möller; Nadine Stadtler; Julia Kretz; Antje Sucker; Agnes Bankfalvi; Elisabeth Livingstone; Lisa Zimmer; Susanne Horn; Annette Paschen; Christoph Plass; Dirk Schadendorf; Eva Hadaschik; Pavlo Lutsik; Klaus Griewank
Journal:  Int J Cancer       Date:  2022-07-11       Impact factor: 7.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.